Isorhamnetin inhibits inflammatory response to alleviate DHEA-induced polycystic ovary syndrome in rats

References

• Norman RJ, Dewailly D, Legro RS, et al. Polycystic ovary syndrome. Lancet. 2007;370(9588):1–7.
   PubMed Web of Science ®Google Scholar
• Katsigianni M, Karageorgiou V, Lambrinoudaki I, et al. Maternal polycystic ovarian syndrome in autism spectrum disorder: a systematic review and meta-analysis. Mol Psychiatry. 2019;24(12):1787–1797.
   PubMed Web of Science ®Google Scholar
• Krishnan A, Muthusami S. Hormonal alterations in PCOS and its influence on bone metabolism. J Endocrinol. 2017;232(2):R99–R113.
   PubMed Web of Science ®Google Scholar
• Seow K-M, Chang Y-W, Chen K-H, et al. Molecular mechanisms of laparoscopic ovarian drilling and its therapeutic effects in polycystic ovary syndrome. IJMS. 2020;21(21):8147.
   Google Scholar
• Jin P, Xie Y. Treatment strategies for women with polycystic ovary syndrome. Gynecol Endocrinol. 2018;34(4):272–277.
   PubMed Web of Science ®Google Scholar
• Collée J, Mawet M, Tebache L, et al. Polycystic ovarian syndrome and infertility: overview and insights of the putative treatments. Gynecol Endocrinol. 2021;37(10):869–874.
   PubMed Web of Science ®Google Scholar
• Cheng X, He B. Clinical and biochemical potential of antioxidants in treating polycystic ovary syndrome. IJWH. 2022;14:467–479.
   Google Scholar
• Lord JM, Flight IHK, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003;327(7421):951–953.
   PubMed Web of Science ®Google Scholar
• Sharpe A, Morley LC, Tang T, et al. Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019;12(12):CD013505–CD013505.
   PubMedGoogle Scholar
• Luo Y, Sun G, Dong X, et al. Isorhamnetin attenuates atherosclerosis by inhibiting macrophage apoptosis via PI3K/AKT activation and HO-1 induction. PLoS ONE. 2015;10(3):e0120259–e0120259.
   PubMed Web of Science ®Google Scholar
• Lu X, Liu T, Chen K, et al. Isorhamnetin: a hepatoprotective flavonoid inhibits apoptosis and autophagy via P38/PPAR-α pathway in mice. Biomed Pharmacother. 2018;103:800–811.
   PubMed Web of Science ®Google Scholar
• Xu Y, Tang C, Tan S, et al. Cardioprotective effect of isorhamnetin against myocardial ischemia reperfusion (I/R) injury in isolated rat heart through attenuation of apoptosis. J Cellular Mol Med. 2020;24(11):6253–6262.
   PubMed Web of Science ®Google Scholar
• Wu Y, Fan L, Wang Y, et al. Isorhamnetin alleviates high glucose-aggravated inflammatory response and apoptosis in oxygen-glucose deprivation and reoxygenation-induced HT22 hippocampal neurons through akt/SIRT1/Nrf2/HO-1 signaling pathway. Inflammation. 2021;44(5):1993–2005.
   PubMed Web of Science ®Google Scholar
• Ren X, Han L, Li Y, et al. Isorhamnetin attenuates TNF-α-induced inflammation, proliferation, and migration in human bronchial epithelial cells via MAPK and NF-κB pathways. Anat Rec (Hoboken). 2021;304(4):901–913.
   PubMedGoogle Scholar
• Lu D-F, Yang L-J, Wang F, et al. Inhibitory effect of luteolin on estrogen biosynthesis in human ovarian granulosa cells by suppression of aromatase (CYP19). J Agric Food Chem. 2012;60(34):8411–8418.
   PubMed Web of Science ®Google Scholar
• Li X, Chen H, Zhang Z, et al. Isorhamnetin promotes estrogen biosynthesis and proliferation in porcine granulosa cells via the PI3K/akt signaling pathway. J Agric Food Chem. 2021;69(23):6535–6542.
   PubMed Web of Science ®Google Scholar
• Li T, Zhang T, Gao H, et al. Tempol ameliorates polycystic ovary syndrome through attenuating intestinal oxidative stress and modulating of gut microbiota composition-serum metabolites interaction. Redox Biol. 2021;41:101886–101886.
   PubMed Web of Science ®Google Scholar
• Guo Z, Chen X, Feng P, et al. Short-term rapamycin administration elevated testosterone levels and exacerbated reproductive disorder in dehydroepiandrosterone-induced polycystic ovary syndrome mice. J Ovarian Res. 2021;14(1):64–64.
   PubMed Web of Science ®Google Scholar
• Orisaka M, Hattori K, Fukuda S, et al. Dysregulation of ovarian follicular development in female rat: LH decreases FSH sensitivity during preantral-early antral transition. Endocrinology. 2013;154(8):2870–2880.
   PubMed Web of Science ®Google Scholar
• Lee JJM, Yin C. Effects of glycyrrhizic acid (GA) in glucose and lipid homeostasis in pcos female rats. Open Conf Proceed J. 2013;4:170–170.
   Google Scholar
• Li Y, Zheng Q, Sun D, et al. Dehydroepiandrosterone stimulates inflammation and impairs ovarian functions of polycystic ovary syndrome. J Cell Physiol. 2019;234(5):7435–7447.
   PubMed Web of Science ®Google Scholar
• Dumitrescu R, Mehedintu C, Briceag I, et al. The polycystic ovary syndrome: an update on metabolic and hormonal mechanisms. J Med Life. 2015;8(2):142–145.
   PubMedGoogle Scholar
• Stener-Victorin E, Holm G, Labrie F, et al. Are there any sensitive and specific sex steroid markers for polycystic ovary syndrome? Obstetric Gynecol Surv. 2010;65(6):383–385.
   Web of Science ®Google Scholar
• Ashraf S, Nabi M, Rasool SUA, et al. Hyperandrogenism in polycystic ovarian syndrome and role of CYP gene variants: a review. Egypt J Med Hum Genet. 2019;20(1).
   Google Scholar
• Yu Y, Cao Y, Huang W, et al. β-Sitosterol ameliorates endometrium receptivity in PCOS-Like mice: the mediation of gut microbiota. Front Nutr. 2021;8:667130–667130.
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhang X. Luteolin alleviates polycystic ovary syndrome in rats by resolving insulin resistance and oxidative stress. Am J Physiol-Endocrinol Metabol. 2021;320(6):E1085–E1092.
   PubMed Web of Science ®Google Scholar
• Kahn SM, Hryb DJ, Nakhla AM, et al. Sex hormone-binding globulin is synthesized in target cells. J Endocrinol. 2002;175(1):113–120.
   PubMed Web of Science ®Google Scholar
• Goldštajn M, Toljan K, Grgić F, et al. Sex hormone binding globulin (SHBG) as a marker of clinical disorders [review]. Coll Antropol. 2016;40(3):211–218.
   PubMedGoogle Scholar
• Deswal R, Yadav A, Dang AS. Sex hormone binding globulin – an important biomarker for predicting PCOS risk: a systematic review and meta-analysis. Syst Biol Reproduct Med. 2018;64(1):12–24.
   PubMed Web of Science ®Google Scholar
• Shorakae S, Ranasinha S, Abell S, et al. Inter-related effects of insulin resistance, hyperandrogenism, sympathetic dysfunction and chronic inflammation in PCOS. Clin Endocrinol (Oxf). 2018;89(5):628–633.
   PubMed Web of Science ®Google Scholar
• Urbano F, Chiarito M, Lattanzio C, et al. Sex Hormone-Binding globulin (SHBG) reduction: the alarm bell for the risk of Non-Alcoholic fatty liver disease in adolescents with polycystic ovary syndrome. Children. 2022;9(11):1748.
   PubMedGoogle Scholar
• Masjedi F, Keshtgar S, Zal F, et al. Effects of vitamin D on steroidogenesis, reactive oxygen species production, and enzymatic antioxidant defense in human granulosa cells of normal and polycystic ovaries. J Steroid Biochem Mol Biol. 2020;197:105521.
   PubMed Web of Science ®Google Scholar
• Pellicer A, Valbuena D, Bauset C, et al. The follicular endocrine environment in stimulated cycles of women with endometriosis: steroid levels and embryo quality. Fertil Steril. 1998;69(6):1135–1141.
   PubMed Web of Science ®Google Scholar
• Mazloomi S, Sanoeei Farimani M, Tayebinia H, et al. The association of mitochondrial translocator protein and voltage-dependent anion channel-1 in granulosa cells with estradiol levels and presence of immature follicles in polycystic ovary syndrome. J Reprod Infertil. 2022;23(3):148–159.
   PubMedGoogle Scholar
• Rojas J, Chávez M, Olivar L, et al. Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth [review]. Int J Reprod Med. 2014;2014(10):719050.
   PubMedGoogle Scholar
• Broskey NT, Tam CS, Sutton EF, et al. Metabolic inflexibility in women with PCOS is similar to women with type 2 diabetes. Nutr Metab. 2018;15(75):018–0312.
   Google Scholar
• Siahaan SCP, Santoso, B, Widjiati. Effectiveness of moringa oleifera leaves on TNF-α expression, insulin levels, glucose levels and follicle count in Rattus norvegicus PCOS model. DMSO. 2022;15:3255–3270.
   Google Scholar
• Hussain L, Aamir N, Hussain M, et al. Therapeutic investigation of standardized aqueous methanolic extract of bitter melon (Momordica charantia L.) for its potential against polycystic ovarian syndrome in experimental animals’ model: in vitro and in vivo studies. Evid-Based Complement Alternat Med. 2022;2022:1–14.
   Web of Science ®Google Scholar
• Abraham Gnanadass S, Divakar Prabhu Y, Valsala Gopalakrishnan A. Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): an update. Arch Gynecol Obstet. 2021;303(3):631–643.
   PubMed Web of Science ®Google Scholar
• Ebejer K, Calleja-Agius J. The role of cytokines in polycystic ovarian syndrome. Gynecol Endocrinol. 2013;29(6):536–540.
   PubMed Web of Science ®Google Scholar
• Gao L, Gu Y, Yin X. High serum tumor necrosis factor-alpha levels in women with polycystic ovary syndrome: a meta-analysis. PLoS ONE. 2016;11(10):e0164021–e0164021.
   PubMed Web of Science ®Google Scholar
• Peng Z, Sun Y, Lv X, et al. Interleukin-6 levels in women with polycystic ovary syndrome: a systematic review and meta-analysis. PLoS ONE. 2016;11(2):e0148531–e0148531.
   PubMed Web of Science ®Google Scholar
• Jackman RW, Rhoads MG, Cornwell E, et al. Microtubule-mediated NF-κB activation in the TNF-α signaling pathway. Exp Cell Res. 2009;315(19):3242–3249.
   PubMed Web of Science ®Google Scholar
• Oróstica L, Astorga I, Plaza-Parrochia F, et al. Proinflammatory environment and role of TNF-α in endometrial function of obese women having polycystic ovarian syndrome. Int J Obes. 2016;40(11):1715–1722.
   Web of Science ®Google Scholar
• Oróstica L, García P, Vera C, et al. Effect of TNF-α on molecules related to the insulin action in endometrial cells exposed to hyperandrogenic and hyperinsulinic conditions characteristics of polycystic ovary syndrome. Reprod Sci. 2018;25(7):1000–1009.
   PubMed Web of Science ®Google Scholar
• Khajouei A, Hosseini E, Abdizadeh T, et al. Beneficial effects of minocycline on the ovary of polycystic ovary syndrome mouse model: molecular docking analysis and evaluation of TNF-α, TNFR2, TLR-4 gene expression. J Reprod Immunol. 2021;144:103289.
   PubMed Web of Science ®Google Scholar
• Lang Q, Yidong X, Xueguang Z, et al. ETA-mediated anti-TNF-α therapy ameliorates the phenotype of PCOS model induced by letrozole [research support, Non-U S Gov’t]. PLoS ONE. 2019;14(6):e0217495.
   PubMed Web of Science ®Google Scholar
• Fischer R, Kontermann RE, Pfizenmaier K. Selective targeting of TNF receptors as a novel therapeutic approach [review]. Front Cell Dev Biol. 2020;8:401.
   PubMed Web of Science ®Google Scholar
• Frankel SK, Cosgrove GP, Cha S-I, et al. TNF-α sensitizes normal and fibrotic human lung fibroblasts to fas-induced apoptosis. Am J Respir Cell Mol Biol. 2006;34(3):293–304.
   PubMed Web of Science ®Google Scholar
• Onalan G, Selam B, Baran Y, et al. Serum and follicular fluid levels of soluble fas, soluble fas ligand and apoptosis of luteinized granulosa cells in PCOS patients undergoing IVF [clinical trial randomized controlled trial]. Hum Reprod. 2005;20(9):2391–2395.
   PubMed Web of Science ®Google Scholar